"We're not doing 30 bets a year": Vijay Pande on betting small after running $4 billion at a16z

"We're not doing 30 bets a year": Vijay Pande on betting small after running $4 billion at a16z

Vijay Pande — who left a16z's roughly $4 billion biotech practice last year to start the much smaller, AI-native VZVC — talks about why biology is finally shifting from a "discovery" science to an "engineering" one, why clinical trials are still brutally expensive, and why he thinks open, shared datasets (not walled-off ones) are what will actually let AI transform medicine.

Vijay Pande Left A $4B Bio Practice To Back Five Companies With AI Agents » Saipien

Why Vijay Pande left a $4B bio practice to make five concentrated bets Vijay Pande built and ran the bio practice at Andreessen Horowitz and is reported to have overseen close to $4 billion in that role. In June of last year he left to co‑found VZVC with Zach Werner, and deliberately shrank the playbook. […]

“We’re not doing 30 bets a year”: Vijay Pande on betting small after running $4 billion at a16z

Vijay Pande - who left a16z's roughly $4 billion biotech practice last year to start the much smaller, AI-native VZVC - talks about why biology is finally shifting from a "discovery" science to an "engineering" one, why clinical trials are still brutally expensive, and why he thinks open, shared datasets (not walled-off ones) are what will actually let AI transform medicine.